Keryx Biopharma (KERX) Posts Q3 EPS of 1c, Beats by 10c
More News related to KERX
- Keryx Biopharmaceuticals (NASDAQ: KERX) Responds to Erroneous Report About Planned Phase III Study for Patients With Colorectal Cancer
- Biopharmaceutical Stock Alert for Keryx Biopharmaceuticals Inc. Issued by InvestorSoup
- Keryx Biopharma (KERX) Reaches Agreement with FDA Regarding SPA on Design of Phase 3 Trial for KRX-0401
- Æterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with Refractory Metastatic Colorectal Ca
- Keryx Biopharmaceuticals Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer
More News related to Earnings
- HNI Corporation (HNI) Tops Q1 EPS by 2c; Revs Light
- Team Health (TMH) Reports Mixed Q4 Results
- Baidu (BIDU) Blows the Lid Off Q4, Shares Jump
- Aspen Insurance (AHL) Posts Q4 adj.-EPS of $1.44, Tops Views
- Acadia Realty Trust (AKR) Misses Q4 FFO by 1c; Guides Below for FY10
Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) reports Q3 EPS of $0.01, 10 cents better than the analyst estimate of ($0.09). Revenue for the quarter was $3.5 million, which compares to the estimate of $320,000.
Related Categories
EarningsStocks Mentioned
+0.04Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
